vs

Side-by-side financial comparison of Legacy Education Inc. (LGCY) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.

Legacy Education Inc. is the larger business by last-quarter revenue ($19.2M vs $18.6M, roughly 1.0× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 10.6%, a 55.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 40.7%).

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.

LGCY vs SCYX — Head-to-Head

Bigger by revenue
LGCY
LGCY
1.0× larger
LGCY
$19.2M
$18.6M
SCYX
Growing faster (revenue YoY)
SCYX
SCYX
+1767.8% gap
SCYX
1808.5%
40.7%
LGCY
Higher net margin
SCYX
SCYX
55.1% more per $
SCYX
65.7%
10.6%
LGCY

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
LGCY
LGCY
SCYX
SCYX
Revenue
$19.2M
$18.6M
Net Profit
$2.0M
$12.3M
Gross Margin
Operating Margin
13.3%
56.3%
Net Margin
10.6%
65.7%
Revenue YoY
40.7%
1808.5%
Net Profit YoY
46.0%
376.5%
EPS (diluted)
$0.15
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGCY
LGCY
SCYX
SCYX
Q4 25
$19.2M
$18.6M
Q3 25
$19.4M
$334.0K
Q2 25
$18.0M
$1.4M
Q1 25
$18.6M
$257.0K
Q4 24
$13.6M
$977.0K
Q3 24
$14.0M
$660.0K
Q2 24
$736.0K
Q1 24
$1.4M
Net Profit
LGCY
LGCY
SCYX
SCYX
Q4 25
$2.0M
$12.3M
Q3 25
$2.2M
$-8.6M
Q2 25
$1.2M
$-6.9M
Q1 25
$2.8M
$-5.4M
Q4 24
$1.4M
Q3 24
$2.1M
$-2.8M
Q2 24
$-14.5M
Q1 24
$411.0K
Operating Margin
LGCY
LGCY
SCYX
SCYX
Q4 25
13.3%
56.3%
Q3 25
13.9%
-2516.5%
Q2 25
11.1%
-701.0%
Q1 25
19.7%
-3350.2%
Q4 24
12.2%
Q3 24
19.1%
-1563.6%
Q2 24
-1255.0%
Q1 24
-692.5%
Net Margin
LGCY
LGCY
SCYX
SCYX
Q4 25
10.6%
65.7%
Q3 25
11.3%
-2572.2%
Q2 25
6.8%
-504.8%
Q1 25
15.2%
-2097.7%
Q4 24
10.3%
Q3 24
14.9%
-425.5%
Q2 24
-1964.4%
Q1 24
29.9%
EPS (diluted)
LGCY
LGCY
SCYX
SCYX
Q4 25
$0.15
$0.25
Q3 25
$0.16
$-0.17
Q2 25
$0.07
$-0.14
Q1 25
$0.21
$-0.11
Q4 24
$0.10
Q3 24
$0.21
$-0.06
Q2 24
$-0.30
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGCY
LGCY
SCYX
SCYX
Cash + ST InvestmentsLiquidity on hand
$21.1M
$40.0M
Total DebtLower is stronger
$660.3K
Stockholders' EquityBook value
$46.1M
$49.4M
Total Assets
$73.1M
$59.0M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGCY
LGCY
SCYX
SCYX
Q4 25
$21.1M
$40.0M
Q3 25
$20.6M
$37.9M
Q2 25
$20.3M
$44.8M
Q1 25
$17.3M
$40.6M
Q4 24
$16.9M
$59.3M
Q3 24
$21.5M
$68.8M
Q2 24
$73.0M
Q1 24
$80.2M
Total Debt
LGCY
LGCY
SCYX
SCYX
Q4 25
$660.3K
Q3 25
$776.9K
Q2 25
$1.4M
Q1 25
$1.0M
Q4 24
$1.1M
Q3 24
$758.2K
Q2 24
Q1 24
Stockholders' Equity
LGCY
LGCY
SCYX
SCYX
Q4 25
$46.1M
$49.4M
Q3 25
$43.7M
$36.4M
Q2 25
$41.0M
$44.5M
Q1 25
$39.3M
$50.5M
Q4 24
$36.4M
$55.1M
Q3 24
$32.6M
$58.5M
Q2 24
$60.4M
Q1 24
$74.1M
Total Assets
LGCY
LGCY
SCYX
SCYX
Q4 25
$73.1M
$59.0M
Q3 25
$72.1M
$51.1M
Q2 25
$69.2M
$60.7M
Q1 25
$67.1M
$67.9M
Q4 24
$62.1M
$90.6M
Q3 24
$50.6M
$99.0M
Q2 24
$107.8M
Q1 24
$118.3M
Debt / Equity
LGCY
LGCY
SCYX
SCYX
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.02×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGCY
LGCY
SCYX
SCYX
Operating Cash FlowLast quarter
$1.1M
$18.4M
Free Cash FlowOCF − Capex
$512.7K
FCF MarginFCF / Revenue
2.7%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
0.52×
1.50×
TTM Free Cash FlowTrailing 4 quarters
$4.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGCY
LGCY
SCYX
SCYX
Q4 25
$1.1M
$18.4M
Q3 25
$1.1M
$-8.7M
Q2 25
$3.0M
$-7.5M
Q1 25
$918.7K
$-7.5M
Q4 24
$659.0K
$-24.0M
Q3 24
$3.2M
$765.0K
Q2 24
$-10.9M
Q1 24
$-4.0M
Free Cash Flow
LGCY
LGCY
SCYX
SCYX
Q4 25
$512.7K
Q3 25
$809.7K
Q2 25
$2.9M
Q1 25
$596.6K
Q4 24
$466.8K
Q3 24
$2.9M
Q2 24
Q1 24
FCF Margin
LGCY
LGCY
SCYX
SCYX
Q4 25
2.7%
Q3 25
4.2%
Q2 25
16.2%
Q1 25
3.2%
Q4 24
3.4%
Q3 24
21.1%
Q2 24
Q1 24
Capex Intensity
LGCY
LGCY
SCYX
SCYX
Q4 25
2.8%
Q3 25
1.3%
Q2 25
0.5%
Q1 25
1.7%
Q4 24
1.4%
Q3 24
1.7%
Q2 24
Q1 24
Cash Conversion
LGCY
LGCY
SCYX
SCYX
Q4 25
0.52×
1.50×
Q3 25
0.48×
Q2 25
2.45×
Q1 25
0.33×
Q4 24
0.47×
Q3 24
1.52×
Q2 24
Q1 24
-9.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGCY
LGCY

Segment breakdown not available.

SCYX
SCYX

Glaxosmithkline Intellectual Property$17.2M92%
Products$1.4M8%

Related Comparisons